Research Article: UBET Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/?-Catenin Signaling Pathway
Introduction:
Glioblastoma (GBM) is the most common malignant primary brain tumor and is associated with higher recurrence and lower survival rates. , Temozolomide (TMZ)-based chemotherapies are the standard treatment options for GBM; however, GBM tumors inevitably become resistant to TMZ and patients have poor prognosis, due to the molecular heterogeneity, hyperactivation of pro-survival pathways, rapid growth rate, and immunosuppression of GBM tumors. Aberrantly activated genes, such as O-methylguanine-DNA methyltransferase (…
Read more